Filovirus vaccines: what challenges are left?

References

• Towner JS, Amman BR, Sealy TK et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog.5, e1000536 (2009).
   PubMed Web of Science ®Google Scholar
• Leroy EM, Kumulungui B, Pourrut X et al. Fruit bats as reservoirs of Ebola virus. Nature438, 575–576 (2005).
   PubMed Web of Science ®Google Scholar
• Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses(Volumn 1). Knipe DM, Howley PM, Griffin DE et al. (Eds). Lippincott-Raven Publishers, PA, USA (2007).
   Google Scholar
• Jaax NK, Davis KJ, Geisbert TJ et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch. Pathol. Lab. Med.120, 140–155 (1996).
   PubMed Web of Science ®Google Scholar
• Pokhodiaev VA, Gonchar NI, Pshenichnov VA. An experimental study of the contact transmission of the Marburg virus. Vopr. Virusol.36, 506–508 (1991).
   PubMed Web of Science ®Google Scholar
• Jaax N, Jahrling P, Geisbert T et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet346, 1669–1671 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol.76, 227–236 (1995).
   PubMed Web of Science ®Google Scholar
• Sergeev AN, Lub M, P’Iankova OG, Kotliarov LA. The efficacy of the emergency prophylactic and therapeutic actions of immunomodulators in experimental filovirus infections. Antibiot. Khimioter.40, 24–27 (1995).
   PubMedGoogle Scholar
• Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology251, 28–37 (1998).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis.8, 503–507 (2002).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature408, 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature424, 681–684 (2003).
   PubMed Web of Science ®Google Scholar
• Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine21, 4071–4080 (2003).
   PubMed Web of Science ®Google Scholar
• Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med.11, 786–790 (2005).
   PubMed Web of Science ®Google Scholar
• Daddario-DiCaprio KM, Geisbert TW, Ströher U et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet367, 1399–1404 (2006).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Jones SM, Daddario-Dicaprio KM et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog.3, e2 (2007).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-DiCaprio KM, Williams KJ et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol.82, 5664–5668 (2008).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A et al. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J. Virol.83, 7296–7304 (2009).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol.15, 460–467 (2008).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Rollin PE, Tate MK et al. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol.81, 6379–6388 (2007).
   PubMed Web of Science ®Google Scholar
• Qiu X, Fernando L, Alimonti JB et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS ONE4, e5547 (2009).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis.196(Suppl. 2), S430–S437 (2007).
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol.13, 1267–1277 (2006).
   PubMed Web of Science ®Google Scholar
• Karron RA, Belshe RB, Wright PF et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J.22, 394–405 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non- human primates. Virology360, 36–49 (2007).
   PubMed Web of Science ®Google Scholar
• Garbutt M, Liebscher R, Wahl-Jensen V et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol.78, 5458–5465 (2004).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Yang L, Zaki SR et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol.80, 2267–2279 (2006).
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol.77, 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE3, e3548 (2008).
   PubMed Web of Science ®Google Scholar
• Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology377, 255–264 (2008).
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Marzi A, Feldmann F et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology383, 348–361 (2009).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol.7, 393–400 (2009).
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis.196(Suppl. 2), S400–S403 (2007).
   PubMed Web of Science ®Google Scholar
• de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J. Exp. Med.202, 1433–1442 (2005).
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol.8, 247–258 (2008).
   PubMed Web of Science ®Google Scholar